INNOVADERM CRO IS NOW INDERO.

Podcast

FILTER BY:

Innovaderm to Indero
Podcast

Episode 38: Eczema, Equity, and Empowerment

Innovaderm to Indero
Podcast

Episode 37: ISF: A New Dimension in Skin Biomarkers

Innovaderm to Indero
Podcast

Episode 36: Clinical Trials Across Asia Pacific

Innovaderm to Indero
Podcast

Episode 35: PTCA – Speaking the Same Language: How Patient Organizations and Sponsors Can Align in Clinical Trials

Innovaderm to Indero
Podcast

Episode 34: Isabel Dorion – Beyond the Checklist: Elevating Clinical Research Associate Oversight for Quality and Impact

Innovaderm to Indero
Podcast

Episode 33: Ana Palijan – Beyond Safety: The Evolving Complexity of Early Phase Studies

Innovaderm to Indero
Podcast

Episode 32: Sarah Ballard – Strategic Storytelling: The Role of PR in Biotech & Pharma Stakeholder Engagement

Innovaderm to Indero
Podcast

Episode 31: Ted Trafford and Brad Hightower – Dos and Don’ts for Sponsors and CROs in Site Collaborations – Part 3: Payments

Innovaderm to Indero
Podcast

Episode 30: Ted Trafford and Brad Hightower – Dos and Don’ts for Sponsors and CROs in Site Collaborations – Part 2: Focus on Protocol

Innovaderm to Indero
Podcast

Episode 29: Ted Trafford and Brad Hightower – Dos and Don’ts for Sponsors and CROs in Site Collaborations – Part 1: Site Engagement

Innovaderm to Indero
Podcast

Episode 28: MĂ©lanie Pomerleau – What is New With ICH E6 (R3)?

Innovaderm to Indero
Podcast

Episode 27: Beatriz Aguirre—How Genuine People Care Drives Business Success

Subscribe to our Podcast.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.